Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2012 Dec;21(12):1845-9. doi: 10.1517/13543784.2012.732065. Epub 2012 Oct 8.

Tetomilast: new promise for phosphodiesterase-4 inhibitors?

Author information

1
Virginia Commonwealth University Medical Center, VCUHS Center for Inflammatory Bowel Disease, MCV Campus, Box 980341, Richmond, VA 23298-0341, USA. sbickston@mcvh-vcu.edu

Abstract

INTRODUCTION:

Tetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). Here, the authors review the pharmacology of the drug, and offer critical review of the available data for use of tetomilast in the treatment of IBD.

AREAS COVERED:

Peer-reviewed publications, including Phase I and II clinical trials, all other formats included.

EXPERT OPINION:

Tetomilast may be beneficial in IBD. Small differences in molecules and in recombinant proteins can translate into substantial differences in clinical effects and toxicity in IBD. This is a reasonable approach when exploring new options like tetomilast.

PMID:
23043390
DOI:
10.1517/13543784.2012.732065
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center